المؤلفون: Nú�ez-Torrón Stock, Claudia, Jiménez Chillón, Carlos, Martín Moro, Fernando, Marquet Palomanes, Juan, Piris Villaespesa, Miguel, Roldán Santiago, Ernesto, Rodríguez Martín, Eulalia, Chinea Rodríguez, Anabelle, García Gutiérrez, Valentín, Moreno Jiménez, Gemma, López Jiménez, Javier, Herrera Puente, Pilar

المصدر: Frontiers in Oncology ; volume 14 ; ISSN 2234-943X

الوصف: Background The measurement of minimal residual disease (MRD) by multiparametric flow cytometry (MFC) before hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML) is a powerful prognostic factor. The interaction of pretransplant MRD and the conditioning intensity has not yet been clarified. Objective The aim of this study is to analyze the transplant outcomes of patients with AML who underwent HSCT in complete remission (CR), comparing patients with positive MRD (MRD+) and negative MRD (MRD−) before HSCT, and the interaction between conditioning intensity and pre-HSCT MRD. Study design We retrospectively analyzed the transplant outcomes of 118 patients with AML who underwent HSCT in CR in a single institution, comparing patients with MRD+ and MRD− before HSCT using a cutoff of 0.1% on MFC, and the interaction between conditioning intensity and pre-HSCT MRD. Results Patients with MRD+ before HSCT had a significantly worse 2-year (2y) event-free survival (EFS) (56.5% vs. 32.0%, p = 0.018) than MRD− patients, due to a higher cumulative incidence of relapse (CIR) at 2 years (49.0% vs. 18.0%, p = 0.002), with no differences in transplant-related mortality (TRM) (2y-TRM, 19.0% and 25.0%, respectively, p = 0.588). In the analysis stratified by conditioning intensity, in patients who received MAC, those with MRD− before HSCT had better EFS ( p = 0.009) and overall survival (OS) ( p = 0.070) due to lower CIR ( p = 0.004) than MRD+ patients. On the other hand, the survival was similar in reduced intensity conditioning (RIC) patients regardless of the MRD status. Conclusions Patients with MRD+ before HSCT have worse outcomes than MRD− patients. In patients who received MAC, MRD− patients have better EFS and OS due to lower CIR than MRD+ patients, probably because they represent a more chemo-sensitive group. However, among RIC patients, results were similar regardless of the MRD status.

الإتاحة: https://doi.org/10.3389/fonc.2024.1394648Test

المؤلفون: Crees, Zachary D., Rettig, Michael P., Jayasinghe, Reyka G., Stockerl-Goldstein, Keith, Larson, Sarah M., Illés, Árpád, Milone, Giulio A., Martino, Massimo, Stiff, Patrick, Sborov, Douglas, Pereira, Denise, Micallef, Ivana, Moreno-Jiménez, Gemma, Mikala, Gábor, Coronel, Maria Liz Paciello, Holtick, Udo, Hiemenz, John, Qazilbash, Muzaffar H., Hardy, Nancy, Latif, Tahir, García-Cadenas, Irene, Vainstein-Haras, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Ickowicz, Debby, Shemesh-Darvish, Liron, Kadosh, Shaul, Gao, Feng, Schroeder, Mark A., Vij, Ravi, DiPersio, John F.

مصطلحات موضوعية: Orvostudományok, Klinikai orvostudományok

الوصف: kzs

وصف الملف: application/pdf

العلاقة: Nature Medicine. -29 : 4 (2023), p. 869-879. -Nat. Med. - 1078-8956; http://dx.doi.org/10.1038/s41591-023-02273-zTest; https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM113622Test; 85153100489; https://hdl.handle.net/2437/357795Test; https://www.nature.com/articles/s41591-023-02273-zTest; 000989808500004

الإتاحة: https://doi.org/10.1038/s41591-023-02273-zTest
https://hdl.handle.net/2437/357795Test
https://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM113622Test
https://www.nature.com/articles/s41591-023-02273-zTest

المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García-Arroba Peinado, José, Cid, Joan, Moraima Jimenez, Maria, Valcarcel, David, Gómez Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, del Rio Garma, Julio

المصدر: Blood Advances. Vol. 6, nº 24, December 2022, pp. 6219 - 6227

مصطلحات موضوعية: caplacizumab, prednisone, rituximab

الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX. ; 9 páginas

وصف الملف: application/pdf

العلاقة: http://hdl.handle.net/10498/29789Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2022008028Test
http://hdl.handle.net/10498/29789Test

المؤلفون: Rumschisky, Pablo Palomo, Núñez, Maria Tenorio, Kennedy, Kyra Velázquez, Martín, Ana Jiménez, Carbonero, Ana Vallés, Rodríguez, Alberto González, Noguerales, Blanca De Felipe, Bolea, Lucia, Jimenez, Francisco Lopez, Moreno-Jiménez, Gemma

المصدر: HemaSphere ; volume 7, issue S3, page e8307322 ; ISSN 2572-9241

الإتاحة: https://doi.org/10.1097/01.hs9.0000976808.83073.22Test

المؤلفون: Mingot-Castellano, María-Eva, García-Candel, Faustino, Martínez-Nieto, Jorge, García-Arroba, José, de la Rubia-Comos, Javier, Gómez-Seguí, Inés, Paciello-Coronel, María-Liz, Valcárcel-Ferreiras, David, Jiménez, Moraima, Cid, Joan, Lozano, Miquel, García-Gala, José-María, Angós-Vazquez, Sonia, Vara-Pampliega, Miriam, Guerra-Domínguez, Luisa, Ávila-Idrobo, Laura-Francisca, Oliva-Hernandez, Ana, Zalba-Marcos, Saioa, Tallón-Ruiz, Inmaculada, Ortega-Sánchez, Sandra, Goterris-Viciedo, Rosa, Moreno-Jiménez, Gemma, Domínguez-Acosta, Lourdes, Araiz-Ramírez, María, Hernández-Mateos, Luis, Flores-Ballesteros, Elena, del Río-Garma, Julio, Pascual-Izquierdo, Cristina, Abio Calvete, Mariola, Albert, Albert, Alberto López García, Alberto, Alegre, Adrian, Alkorta Eizagirre, Aitziber, Alonso Escobar, María Nieves, Alonso Madrigal, Cristina, Amunarriz, Cristina, Antelo Caamaño, María Luisa, Arbona Castaño, Cristina, Ballester Ruiz, Maria Carmen, Ballina Martín, Belén, Berberana Fernández de Murias, Margarita, Berrueco Moreno, Ruben, Bueno, Jose Luis, Calderón López, María Teresa, Chica Gullón, Esther, Cid Vidal, Joan, Contreras Barbeta, Enric, Cuéllar Pérez-Ávila, Clara, de la Rubia Comos, Javier, Del Orbe Barreto, Rafael Andres, Del Río Garma, Julio, Díaz Valdés, José R., Diaz-Ricart, Maribel, Diez Gallarreta, Zuriñe, Dueñas Hernando, Virginia, Eguia, Blanca, Escoda, Lourdes, Fernández Docampo, Marta, Fernandez Fuertes, Fernando, Fernández Muñoz, Hermogenes, Fernández Sánchez de Mora, Maria Carmen, Fernandez Zarzoso, Miguel, Fidalgo, Teresa, Flores Ballester, Elena, Fonte Feal, Cristina, Galvez, Francisco Javier, Garcia Arroba Peinado, Jose, García Candel, Faustino, Garcia Erce, Jose Antonio, García Gala, José María, Gimeno, JJ, Gómez, Delia, Gómez Seguí, Inés, Gomez Vazquez, Maria Jesus, Gonzalez, Carlos, González Fernández, Fernando Ataulfo, Gonzalez Porras, Jose Ramon, Gonzalez Rodriguez, Victoria Paz, Goterris Viciedo, Rosa, Guerra Domínguez, Luisa, Guillén García, Helga, Hernandez, Adoracion, Hernández Castellet, José Carlos, Hernandez Mohedo, Francisca, Hernandez Vazquez, Laura, Hidalgo Soto, Marta, Hong Tam, Azueg Hang, Kerguelen Fuentes, Ana Lilia, Leal Bento, Marta, Lopes, Raquel, López, Olga, López Chuliá, Francisca, Maria Jose Busto, Maria Jose, Martín Hernández, María Paz, Martinez Estefano, Elvira, Martinez Nieto, Jorge, Martinez Redondo, Consuelo, Martinez Revuelta, Eva, Medina Marrero, Laura, Mingot Castellano, María Eva, Morales Sanz, María Dolores, Moreno, Gemma, Moreno Beltrán, Mª Esperanza, Moreno Chulilla, Jose Antonio, Nistal Gil, Sara, Oliva Hernandez, Ana Yurena, Pascual, Teresa, Pascual Izquierdo, Crisina, Paumard Rodríguez, Elena, Pecos, Patricia, Peña Marcos, Francisco, Pereira Coelho, Daniela Sofia, Pérez Segura, Gloria Maria, Perez-Lopez, Olga, Prieto Pareja, Elena, Ramiro, Laia, Richart López, Luis Alberto, Rodriguez Dominguez, Maria Jesus, Rodriguez Nuñez, Antonio, Ruiz Sainz, María Elena, Saez Serrano, Isabel, Salinas Argente, Ramón, Sanchez, Maria Elena, Sanchez Anton, Piva, Sánchez Fernández, Mª Soledad, Sebastian, Elena, Simona, Gabriela, Solanich Moreno, Xabier, Soledad Casado, Soledad, Tallón, Jose David, Turcu, Violeta, Valledor Méndez, Manuel, Vidan Y Estevez, Julia, Viejo Llorente, Aurora, Bienert, Álvaro, Serrano, Alfons, Llorente, Laura, Campuzano, Verónica, Tallón, Inmaculada, Pons, Verónica, Linares, Mónica, Valles, Ana, Martínez Francés, Antonio, Freiria, Carmen, González Arias, Elena, Araujo, Enmanuel, Marco de Lucas, Fernando, López, Juan Antonio, Uribe Barrientos, Marisol, Calviño, Michael, Gómez Calafat, Montse, Marco Vera, Pascual, Fariña, Sabela, Zalba, Saioa, Monsalvo, Silvia, Escamilla, Virginia

المصدر: Blood; May 2024, Vol. 143 Issue: 18 p1807-1815, 9p

مستخلص: •There is no delay in ADAMTS13 recovery after PEX start in caplacizumab–treated patients with iTTP from the Spanish registry.•Caplacizumab allows suspending PEX earlier, thus creating the impression that there is a delay in ADAMTS13 recovery after PEX end.

المؤلفون: Crees, Zachary D, Rettig, Michael P., Jayasinghe, Reyka, Stockerl-Goldstein, Keith, Larson, Sarah M, Arpad, Illes, Milone, Giuseppe, Martino, Massimo, Stiff, Patrick J., Sborov, Douglas, Pereira, Denise, Micallef, Ivana N, Moreno-Jiménez, Gemma, Mikala, Gabor, Coronel, Maria L Paciello, Holtick, Udo, Hiemenz, John, Qazilbash, Muzaffar H., Hardy, Dr. Nancy Maureen, Latif, Tahir, Garcia-Cadenas, Irene, Vainstein-Haras, Abi, Sorani, Ella, Gliko-Kabir, Irit, Goldstein, Inbal, Ickowicz, Debby, Darvish, Liron, Kadosh, Shaul, Gao, Feng, Schroeder, Mark A., Vij, Ravi, DiPersio, John F.

المصدر: Transplantation and Cellular Therapy ; volume 30, issue 2, page S390-S391 ; ISSN 2666-6367

مصطلحات موضوعية: Transplantation, Cell Biology, Hematology, Molecular Medicine, Immunology and Allergy

الإتاحة: https://doi.org/10.1016/j.jtct.2023.12.548Test
https://api.elsevier.com/content/article/PII:S2666636723022832?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666636723022832?httpAccept=text/plainTest

المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García Arroba Peinado, José, Cid Vidal, Joan, Jimenez, Maria Moraima, Valcarcel, David, Gómez Seguí, Inés, Rubia, Javier de la, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, Rio Garma, Julio del, Spanish Apheresis Group (GEA), Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT)

المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

مصطلحات موضوعية: Rituximab, Trombosi, Assaigs clínics, Thrombosis, Clinical trials

الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.

وصف الملف: 9 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2022008028Test; Blood Advances, 2022, vol. 6, num. 24, p. 6219-6227; https://doi.org/10.1182/bloodadvances.2022008028Test; http://hdl.handle.net/2445/196688Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2022008028Test
http://hdl.handle.net/2445/196688Test

المؤلفون: Pérez‐Lamas, Lucía, Moreno‐Jiménez, Gemma, Tenorio‐Núñez, María C., Velázquez‐Kennedy, Kyra, Jiménez‐Chillón, Carlos, Astibia‐Mahillo, Beatriz, Núñez‐Torrón, Claudia, García‐Gutiérrez, Valentín, Jiménez‐Martín, Ana, Vallés‐Carboneras, Ana, López‐Jiménez, Javier F.

المصدر: American Journal of Hematology ; volume 96, issue 8 ; ISSN 0361-8609 1096-8652

الإتاحة: https://doi.org/10.1002/ajh.26214Test

المؤلفون: Velázquez‐Kennedy, Kyra, Luna, Alejandro, Sánchez‐Tornero, Adrián, Jiménez‐Chillón, Carlos, Jiménez‐Martín, Ana, Vallés Carboneras, Ana, Tenorio, María, García García, Irene, López‐Jiménez, Francisco Javier, Moreno‐Jiménez, Gemma

المصدر: Transfusion ; volume 61, issue 2, page 361-367 ; ISSN 0041-1132 1537-2995

الوصف: Background During the COVID‐19 outbreak, most hospitals deferred elective surgical procedures to allow space for the overwhelming number of COVID‐19 patient admissions, expecting a decrease in routine blood component requirements. However, because transfusion support needs of COVID‐19 patients are not well known, its impact on hospital blood supply is uncertain. The objective of this study was to assess the effect of the COVID‐19 pandemic on transfusion demand. Study Design and Methods Transfusion records during the peak of the COVID‐19 pandemic (March 1‐April 30, 2020) were reviewed in our center to assess changes in blood requirements. Results During this period 636 patients received a total of 2934 blood components, which reflects a 17.6% reduction in transfusion requirements with regard to the same period of 2019, and blood donations in Madrid dropped by 45%. The surgical blood demand decreased significantly during the outbreak (50.2%). Blood usage in the hematology and oncology departments remained unchanged, while the day ward demand halved, and intensive care unit transfusion needs increased by 116%. A total of 6.2% of all COVID inpatients required transfusion support. COVID‐19 inpatients consumed 19% of all blood components, which counterbalanced the savings owed to the reduction in elective procedures. Conclusion Although only a minority of COVID‐19 inpatients required transfusion, the expected reduction in transfusion needs caused by the lack of elective surgical procedures is partially offset by the large number of admitted patients during the peak of the pandemic. This fact must be taken into account when planning hospital blood supply.

الإتاحة: https://doi.org/10.1111/trf.16171Test

المؤلفون: Núñez-Torrón, Claudia, García-Gutiérrez, Valentín, Tenorio-Núñez, María Concepción, Moreno-Jiménez, Gemma, López-Jiménez, Francisco Javier, Herrera-Puente, Pilar

المصدر: Bone Marrow Transplantation ; volume 56, issue 1, page 267-269 ; ISSN 0268-3369 1476-5365

مصطلحات موضوعية: Transplantation, Hematology

الإتاحة: https://doi.org/10.1038/s41409-020-0961-yTest
http://www.nature.com/articles/s41409-020-0961-y.pdfTest
http://www.nature.com/articles/s41409-020-0961-yTest